Real-World Data Shows Lucid Diagnostics’ EsoCheck is Well-tolerated

Newly presented real-world data (RWD) at a special conference of the American Association for Cancer Research shows that Lucid Diagnostics’ EsoCheck medical device is well tolerated when used in the early detection of esophageal precancer. The study used data taken from 687 patients, finding that 98% of patients completed the procedure. Moreover, DNA was successfully extracted from 90% of patients.

According to Lucid’s CEO Lishan Aklog, MD, “EsoCheck remains the only commercially-available, nonendoscopic esophageal cell collection device recommended by major professional society guidelines for early detection of esophageal precancer to prevent esophageal cancer deaths. These unprecedented results in a large cohort of patients demonstrate that EsoCheck can be successfully performed in nearly all patients and is broadly well-tolerated.”

To read more, click here.

(Source: Business Wire, December 1^st, 2022)